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The number of people with asthma continues to grow around the world, and asthma remains a poorly controlled disease despite
the availability of management guidelines and highly effective medication. Patient noncompliance with therapy is a major reason
for poor asthma control. Patients fail to comply with their asthma regimen for a wide variety of reasons, but incorrect use of
inhaler devices is amongst themost common.The pressurisedmetered-dose inhaler (pMDI) is still themost frequently used device
worldwide, but many patients fail to use it correctly, even after repeated tuition. Breath-actuated inhalers are easier to use than
pMDIs. The rationale behind inhaler choice should be evidence based rather than empirical. When choosing an inhaler device, it
is essential that it is easy to use correctly, dosing is consistent, adequate drug is deposited in both central and peripheral airways,
and that drug deposition is independent of airflow. Regular checking of inhalation technique is crucial, as correct inhalation is one
of the cornerstones of successful asthma management.
1. Introduction
The incidence of asthma continues to rise worldwide, dou-
bling over the last 10 years [1–4] and, consequently, asthma
places a huge economic burden on healthcare resources [5].
Asthma management guidelines [1, 2] are now available in
virtually every country; their aim is to achieve control of
the disease with the lowest possible dose of medication
prescribed [1, 2]. To this end, asthma guidelines advocate a
stepwise pharmacological approach that consists in increas-
ing (“step up”) the numbers of medications as asthma wors-
ens, and decreasing (“step down”) medications when asthma
is under control [1, 2]. Once control of asthma has been
achieved and maintained for at least three months, a gradual
reduction of the maintenance therapy is recommended to
identify the minimum therapy required to maintain control
[1, 2]. Unfortunately, the current level of asthma control falls
far short of the goals for long-term asthma management
[2, 6, 7], with many patients reporting day- and night-time
symptoms at least once a week, and continuing to require
unscheduled visits and hospitalisations [2, 6, 7]. One of
the reason why asthma remains poorly controlled is that
patients are deriving incomplete benefit from their inhaled
medication, primarily because they are unable to use their
inhalers correctly [8–11].
The benefits of inhaled therapy for the treatment of
obstructive airway diseases, such as asthma, have been recog-
nised for many years. In comparison with oral or parenteral
formulations, minute but therapeutic doses of drug are deliv-
ered topically into the airways causing local effects within
the lungs [12–14]. Unwanted systemic effects are minimised
as the medication acts with maximum pulmonary specificity
together with a rapid onset and duration of action [12–
14]. Consequently, aerosol formulations of bronchodilators
and corticosteroids are the mainstay of modern treatment
for asthma at all ages [1, 2]. Aerosols are either solutions
containing medications, or suspensions of solid particles in a
gas, generated from devices such as pressurisedmetered dose
inhalers (pMDIs), dry powder inhalers (DPIs) or nebulisers
[12–16]. In the past decade some novel delivery systems have
been developed that have high delivery efficiencies; notable
among these are the soft mist inhalers (SMI). Each type of
inhaler device has pros as well as cons (Table 1). Inhalers differ
in their efficiency of drug delivery to the lower respiratory
tract, depending on the form of the device, its internal
resistance, formulation of medication, particle size, velocity
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Table 1: Major components, advantages, and disadvantages of inhaler devices.
Inhaler Formulation Metering system Advantages Disadvantages
pMDI
Drug suspended or
dissolved in
propellant (with
surfactant and
cosolvent)
Metering valve
and reservoir
Portable and compact
Multidose device
Relatively cheap
Cannot contaminate contents
Available for most inhaled medications
Contains propellants
Not breath-actuated
Many patients cannot use it correctly
High oropharyngeal deposition
pMDI +
spacer
Easier to coordinate
Large drug doses delivered more
conveniently
Less oropharyngeal deposition
Higher lung deposition than a pMDI
Less portable than pMDI
Plastic spacers may acquire static
charge
Additional cost to pMDI
BA-MDI Drug suspended inpropellant
Metering valve
and reservoir
Portable and compact
Multidose device
Breath-actuated (no coordination
needed)
Cannot contaminate contents
Contains propellants
“Cold Freon” effect
Requires moderate inspiratory flow to
be triggered
DPI
Drug blend in
lactose, drug alone,
drug/excipient
particles
Capsules,
blisters,
multidose
blister packs
reservoirs
Portable and compact
Breath-actuated (no coordination
needed)
Does not contain propellants
Requires a minimum inspiratory flow
May not appropriate for emergency
situations
Many patients cannot use it correctly
Most types are moisture sensitive
SMI
(Respimat)
Aqueous solution
or suspension
Unit dose
blisters or
reservoirs
Portable and compact
Multidose device
High lung deposition
Does not contain propellants
Not breath-actuated
Not currently available in most
countries
Relatively expensive
Nebulisers Aqueous solutionor suspension
Nebule
dispensed into
reservoir
chamber of
nebulizer
May be used at any age
No specific inhalation technique
required
Vibrating mesh is portable and does
not require an outside energy source
May dispense drugs not available with
pMDIs or DPIs
Jet and ultrasonic nebulisers require an
outside energy source
Treatment times can be long
Performance varies between nebulisers
Jet nebulisers cannot aerosolise a
certain volume of solution
Risk of bacterial contamination
Newer nebulisers are expensive
pMDI: pressurised metered-dose inhalers; BA-MDI: breath-actuated metered-dose inhaler; DPI: dry-powder inhaler; SMI: soft mist inhaler.
of the produced aerosol plume, and ease with which patients
can use the device [12–16]. Efficiency of drug delivery may
also be influenced by patients’ preference, which in turn
affects patients’ adherence with treatment and indeed long-
term control of the disease [17]. There seems little point
in prescribing an effective medication in an inhaler device
which patients cannot use correctly. Thus, the choice of the
right inhaler for the patient is just as important as choosing
the most effective medication.
In this paper, the hand-held inhalers are reviewed
together with a current understanding about correct inhala-
tion techniques for each device. A description of nebulisers,
which are frequently used to deliver asthmamedications [18],
is also given. However, since most current nebuliser designs
are bulky and inconvenient and drug administration is
prolonged, they are better categorised as second-line devices
for most asthma patients. Finally, we present recommenda-
tions from the Aerosol Drug Management Improvement Team
(ADMIT) for inhaler selection, as well as an algorithm for
asthma therapy adjustment [8].
2. Aerosol Device Options
2.1. Pressurised Metered-Dose Inhalers. The development of
the first commercial pMDIs was carried out by Riker Labo-
ratories in 1955 and marketing in 1956 as the first portable,
multidose delivery system for bronchodilators. Since that
time, the pMDI has become the most widely prescribed
inhalation device for drug delivery to the respiratory tract to
treat obstructive airway diseases such as asthma and chronic
obstructive pulmonary disease [18]; the total worldwide sales
by all companies of pMDI products run in excess of $2 billion
per year. The pMDI (Figure 1) is a portable multidose device
that consists of an aluminium canister, lodged in a plastic
support, containing a pressurised suspension or solution
of micronized drug particles dispersed in propellants. A
surfactant (usually sorbitan trioleate or lecithin) is also added
to the formulation to reduce the particle agglomeration and
is responsible for the characteristic taste of specific inhaler
brands. The key component of the pMDI is a metering valve,
which delivers an accurately known volume of propellant,
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Components Formulation
Container
Actuator 
seals
Metering
valve 
Active drug
Propellants
Cosolvents
Metering of 
a single dose
Pressing the stem disconnects 
the metering chamber
Discharge of the dose 
from the metering chamber
Actuator 
nozzle
Valve
stem groove Valve
stem orifice
Spray orifice
Figure 1: Components of a pressurised metered-dose inhaler. Lower panels illustrate the process of aerosol generation.
containing the micronised drug at each valve actuation.
Pressing the bottom of the canister into the actuator seat-
ing causes decompression of the formulation within the
metering valve, resulting in an explosive generation of a
heterodisperse aerosol of droplets that consist of tiny drug
particles contained within a shell of propellant. The latter
evaporates with time and distance, which reduces the size of
the particles that use a propellant under pressure to generate
a metered dose of an aerosol through an atomisation nozzle
(Figure 1). The technology of pMDI has evolved steadily over
the period of mid-1950s to the mid-1980s. Until recently,
the pMDI used chlorofluorocarbons (CFCs) as propellants
to deliver drugs; however, in accordance with the Mon-
treal Protocol of 1987, CFC propellants are being replaced
by hydrofluoroalkane (HFA) propellants that do not have
ozone depleting properties [19]. Hydrofluoroalkane 134a and
227ca are propellants that contain no chlorine and have a
residence in the stratosphere lower than CFCs, so they have
substantially less global warming potential than do CFCs.
HFA-134a albuterol has been the first HFA-driven pMDI
that has received approval in both Europe and the United
States. This preparation consists of albuterol suspended in
HFA-134a, oleic acid, and ethanol; clinical trials have shown
this preparation to be bioequivalent to CFCs albuterol in
both bronchodilator efficacy and side effects [20]. At the
present, inmost European countriesCFC-driven pMDIs have
totally been replaced by HFA inhalers. The components of
CFC-driven pMDIs (i.e., canister, metering valve, actuator,
and propellant) are retained in HFA-driven pMDIs, but
they have had a redesign. Two approaches were used in
the reformulation of HFA-driven pMDIs. The first approach
was to show equivalence with the CFC-driven pMDI, which
helped regulatory approval, delivering salbutamol and some
corticosteroid. Some HFA formulations were matched to
their CFC counterparts on a microgram for microgram
basis; therefore, no dosage modification was needed when
switching from a CFC to an HFA formulation. The second
approach involved extensive changes, particularly for corti-
costeroid inhalers containing beclomethasone dipropionate,
and resulted in solution aerosols with extra-fine particle
size distributions and high lung deposition [21, 22]. The
exact dose equivalence of extra-fine HFA beclomethasone
dipropionate and CFC beclomethasone dipropionate has not
been established, but data from most trials have indicated
a 2 : 1 dose ratio in favour of the HFA-driven pMDI [21,
22]. Patients on regular long-term treatment with a CFC
pMDI could safely switch to an HFA pMDI without any
deterioration in pulmonary function, loss of disease control,
increased frequency of hospital admissions, or other adverse
effects [19]. However, when physicians prescribe HFA for-
mulations in place of CFC versions for the first time, they
should inform their patients about differences between these
products. Compared with CFC-driven pMDIs, many HFA-
driven pMDIs have a lower (25.5mN versus 95.4mN) impact
force and a higher (8∘C versus −29∘C) temperature [12, 14].
These properties partially overcome the “cold Freon effect”
[12, 14] that has caused some patients to stop inhaling their
CFC pMDIs. In addition, most HFA pMDIs have a smaller
delivery orifice that may result in a more slowly delivered
aerosol plume, thus facilitating inhalation and producing less
mouth irritation [23]. Another difference is that many HFA-
driven pMDIs contain small amount of ethanol. This affects
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the taste, as well as further increasing the temperature and
decreasing the velocity of the aerosol. PressurizedMDIs con-
taining fixed combination of beclomethasone dipropionate
and the long-acting bronchodilator formoterol in a solution
formulation with HFA-134a and ethanol with cosolvent [21,
24, 25] have been developed (Modulite technology, Chiesi,
Italy). Interestingly, this formulation dispenses an aerosol
that has a particularly small particle size (mass median
aerodynamic diameter ∼1𝜇), a lower plume velocity of the
aerosol, and not dropping temperature as much as when
CFCs are used as carriers. These three factors, that is, smaller
particle size, lower plume velocity, and less temperature drop,
may decrease upper airway impaction and increase airway
deposition of particles, particularly to the smaller airways,
compared with the same dose of drug administered from a
CFC pMDI [24, 25].
Pressurised MDIs have a number of advantages (Table 1):
they are compact, portable, relatively inexpensive, and
contain at least 200 metered doses per canister that are
immediately ready for the use. Furthermore, a large fraction
(approximately 40%) of the aerosol particles is in the res-
pirable range (mass median aerodynamic diameter less than
5 𝜇), and dosing is generally highly reproducible from puff to
puff [12–16]. Despite these advantages, most patients cannot
use pMDIs correctly, even after repeated tuition [8–11].
This is because pMDIs require good coordination of patient
inspiration and inhaler actuation to ensure correct inhalation
and deposition of drug in the lungs. The correct inhalation
technique when using pMDIs involves firing the pMDI while
breathing in deeply and slowly, continuing to inhale after
firing, and then following inhalation with a breath-holding
pause to allow particles to sediment on the airways [12, 26].
The patients should also be instructed that, on the first use
and after several days of disuse, the pMDI should be primed.
However, patients frequently fail to continuously inhale
slowly after activation of the inhaler and exhale fully before
inhalation [8]. In addition, patients often activate the inhaler
before inhalation or at the end of inhalation by initiating
inhaler actuation while breath holding [8]. Crompton and
colleagues [8, 27, 28] showed that the proportion of patients
capable of using their pMDIs correctly after reading the
package insert fell from 46% in 1982 to 21% in 2000, while
only just over half of patients (52%) used a pMDI correctly
even after receiving instruction. In a large (𝑛 = 4078)
study, 71% of patients were found to have difficulty using
pMDIs, and almost half of them had poor coordination [29].
Incorrect inhalation technique was associated with poor
asthma control and with poor pMDI users having less stable
asthma control than good pMDI users [29].
Even with correct inhalation technique, pMDIs are inef-
ficient since no more than 20% for CFC pMDIs or 40%–50%
for HFA pMDIs producing extra-fine particles [12, 14–16] of
the emitted dose reaches the lungs with a high proportion of
drug being deposited in the mouth and oropharynx which
can cause local as well as systemic side effects due to rapid
absorption [12, 14–16]. Another disadvantage of some pMDIs
is the absence of built-in counters that would alert the
patient to the fact that the inhaler was approaching “empty”
and needed to be refilled. Although many pMDIs contain
more than the labelled number of doses, drug delivery
per actuation may be very inconsistent and unpredictable
after the labelled number of actuations. Beyond the labelled
number of actuations, propellants can release an aerosol
plume that contains little or no drug, a phenomenon called
tail-off [30].
2.2. pMDI Accessory Devices: The Spacers and Valved Holding
Chambers. Although the term “spacers” is often used for all
types of extension add-on devices, these devices are properly
categorised as either “spacers” or “valved holding chambers.”
A spacer (Figure 2) is a simple tube or extension attached
to the pMDI mouthpiece with no valves to contain the
aerosol plume after pMDI actuation [31]. A valved holding
chamber (Figure 2) is an extension device, added onto the
pMDI mouthpiece or canister, that contains a one-way valve
to prevent holding the aerosol until inhalation [31]. The
direction of the spray can be forward, that is, toward the
mouth, or reverse, that is, away from the mouth (Figure 2).
Both spacers and holding chambers constitute a volume into
which the patient actuates the pMDI and from which the
patient inhales reducing the need to coordinate the two
manoeuvres [31]. By acting as an aerosol reservoir, these
devices slow the aerosol velocity and increase transit time
and distance between the pMDI actuator and the patient’s
mouth, allowing particle size to decrease and, consequently,
increasing deposition of the aerosol particles in the lungs [31].
Moreover, because spacers trap large particles comprising
up to 80% of the aerosol dose, only a small fraction of the
dose is deposited in the oropharynx, thereby reducing side
effects, such as throat irritation, dysphonia, and oral can-
didiasis, associated with medications delivered by the pMDI
alone [31]. Large-volume holding chambers increase lung
deposition to a greater degree than does tube spacer or small
holding chamber [32–34]. Devices larger than 1 L, however,
are impractical, and patients would have difficulty inhaling
the compete contents [35]. A valved holding chamber fitted
with an appropriate facemask is used to give pMDI drugs to
neonates, young children, and elderly patients. The two key
factors for optimum aerosol delivery are a tight but comfort-
able facemask fit and reduced facemask dead space [31, 36].
Because children have low tidal volumes and inspiratory flow
rates, comfortable breathing through a facemask requires low
resistance inspiratory or expiratory valves. Of note, some
holding chambers incorporate a whistle that makes a sound
if inspiration is too fast [36]. Training patients to ensure that
the whistle does not sound assists with developing an optimal
inhalation technique. Plastic bottles and cups can also be used
as rudimental, home-made spacers for the administration
of aerosol drugs [37–39]. In a randomized controlled trial
clinical effects of salbutamol inhaled through pMDI with a
home-made nonvalved spacer (500mL mineral water plastic
bottle) were compared with those when the same drug was
administered by using an oxygen-drivennebuliser in children
with asthma [39]. The number of children hospitalised after
treatment changes in clinical score and oxygen saturation
were similar in conventional and bottle spacer groups [39].
Valved holding chambers may improve the clinical effect
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(a) (b) (c)
Figure 2: (a) The Jet open tube spacer; (b) the AeroChamber plus holding chamber; (c) the reverse-flow EZSpacer.
of inhaled medications especially in patients unable to use
a pMDI properly [31]. Indeed, compared to both pMDIs
alone and DPIs, these devices may increase the response to
short-acting 𝛽-adrenergic bronchodilators, even in patients
with correct inhalation technique [40–43]. While spacers
and valved holding chambers are good drug-delivery devices,
they suffer from the obvious disadvantage of making the
entire delivery system less portable and compact than a pMDI
alone. The size and appearance of some spacers may detract
from the appeal of the pMDI to patients, especially among
the paediatric population, and negatively affect patients’
compliance [31]. Furthermore, spacers are not immune
from inconsistent medication delivery caused by electrostatic
charge of the aerosol [44–47]. Drug deposits can build up on
walls of plastic spacers and holding chambers mostly because
of electrostatic charge. Aerosols remain suspended for longer
periodswithin holding chambers that aremanufactured from
nonelectrostatic materials than other materials. Thus, an
inhalation might be delayed for 2–5 s without a substantial
loss of drug to the walls of metal or nonstatic spacers
[45–47]. The electrostatic charge in plastic spacers can be
substantially reduced by washing the spacer with a diluted
(1 : 5000) household detergent and allowing it to drip dry
[14, 48]. There is no consensus on how often a spacer should
be cleaned, but recommendations range in general from once
a week to once a month [12]. Multiple actuations of a pMDI
into a spacer before inhalation also reduces the proportion
of drug inhaled [46–50]. Five actuations of a corticosteroid
inhaler into a large-volume spacer before inhalation deliver a
similar dose to a single actuation into the same spacer inhaled
immediately [49].
2.3. Breath-Actuated Metered-Dose Inhaler. Breath-actuated
(BA) pMDIs are alternatives to conventional press-and-
breath pMDIs developed to overcome the problem of poor
coordination between pMDI actuation and inhalation [12,
51]. Examples of this type of device include the Autohaler
(3M, St. Paul,MI) and the Easi-Breathe (Teva Pharmaceutical
Industries Ltd). Breath-actuated pMDIs contain a conven-
tional pressurised canister and have a flow-triggered system
driven by a spring which releases the dose during inhalation,
so that firing and inhaling are automatically coordinated
[12, 51]. These inhalation devices (Table 1) can achieve good
lung deposition and clinical efficacy in patients unable to use
a pMDI correctly because of coordination difficulties [52].
Errors when using BApMDI are less frequent than when
using a standard pMDI [17]. Increased use of BApMDIs
might improve asthma control and reduce overall cost of
asthma therapy compared with conventional pMDIs [53].
On the negative side (Table 1), BApMDIs do not solve cold
Freon effect and would be unsuitable for a patient who
has this kind of difficulty using pMDI. In addition, these
devices require a relatively higher inspiratory flow than pMDI
for triggering. Furthermore, oropharyngeal deposition with
breath-actuated pMDIs is as high as that with CFC-pMDIs
[54].
The Autohaler is a BApMDI that is available with
albuterol and behlomethasone in HFA propellant. It has
a manually operated lever that, when lifted, primes the
inhaler through a spring-loaded mechanism, allowing the
aerosol to be dispensed with an inspiratory flow of about
30 L/min. Clinical studies have demonstrated that the lung
deposition of 𝛽-adrenergic bronchodilator administered via
the Autohaler is similar to that obtained when the drug
is correctly inhaled via a pMDI and greater than that
resulting from conventional pMDIs in patients with poor
inhalation technique [54].Moreover, it can be used effectively
by patients with poor lung function, patients with limited
manual dexterity, and elderly patients [54]. The Easi-Breathe
is a patient-triggered inhaler that dispenses albuterol and
beclomethasone.This inhaler is primedwhen themouthpiece
is opened. When the patient breathes in, the mechanism
is triggered and a dose is automatically released into the
airstream. The inhaler can be actuated at a very low airflow
rate of approximately 20 L/min, which is readily achievable by
most patients [55]. Not surprisingly, practice nurses found it
easier to teach and patients to use than a conventional pMDI
[55]. In vitro studies have shown that particle size distribution
and percentage of respirable fine particle obtained by using
the Easi-Breathe device were similar to those obtained by
using the conventional pMDI [56], although comparative
clinical efficacy data are not yet available.
2.4. Dry Powder Inhalers. Modern dry powder inhalers were
first introduced in 1970, and the earliest models were single-
dose devices containing the powder formulation in a gelatin
capsule, which the patient loaded into the device prior to
use. Since the late 1980s multidose DPIs have been available,
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Dry powder inhalers
Nonreusable dry powder
inhalers
Reusable dry powder
inhalers
Single dose 
systems 
Multiple dose
systems
Multiple dose
systems
Single dose 
systems 
Diskus Turbuhaler Easyhaler Aerolizer Rotadisk Novolizer 
Useable for 
60SD 200 SD 200 SD 50SD 3months 1 year
SD: single dose
Figure 3: Examples of dry powder inhalers. From [57].
giving the same degree of convenience as a pMDI [58]. Dry-
powder inhalers (Figure 3) are delivery devices containing
drugs in powdered formulation that have been milled to
produce micronized particles in the respirable range. These
delivery devices allow the particles to be deagglomerated
by the energy created by the patient’s own inspiratory flow
[58–60]. The powdered drug can be either pure or blended
with large particle size excipient (usually lactose) as a carrier
powder [58–60]. The empty condition is generally apparent,
alerting the patient to the need for replacement. Some DPIs,
such as for the HandiHaler (Boehringer Ingelheim, D) and
the Aerolizer (Novartis Pharma, CH), are singledose devices
in which a capsule of powder is perforated in the device
with needles fixed to pressure buttons. Other types of DPIs,
such as the Diskus (GlaxoSmithKline, UK) or the Turbuhaler
(AstraZeneca, Sweden), have a multidose capacity. These
multidose DPIs fall into twomain categories (Figure 3): these
eithermeasure the dose themselves (fromapowder reservoir)
or they dispense individual doses which are premetered
into blisters by the manufacturer [58–60]. Turbuhaler and
Diskus, respectively, are representatives of the former and
latter categories, although many other different designs are
presently in development. To date, new innovative DPIs
are available for treatment of asthma and for delivery of a
range of drugs usually given by injection, such as peptides,
proteins, and vaccines. The use of DPIs is expected to
increase with the phasing out of CFC production along with
increased availability of drug powders and development of
novel powder devices [59].
Generally, DPIs do have many advantages (Table 1). Dry
powder inhalers are actuated and driven by patient’s inspi-
ratory flow; consequently, DPIs do not require propellants
to generate the aerosol, as well as coordination of inhaler
actuation with inhalation [60]. However, a forceful and
deep inhalation through the DPI is needed to deaggregate
the powder formulation into small respirable particles as
efficiently as possible and, consequently, to ensure that the
drug is delivered to the lungs [60–62]. Although most
patients are capable of generating enough flow to operate
a DPI efficiently [60], the need to inhale forcefully and,
consequently, generate a sufficient inspiratory flow could
be a problem for very young children or patients with
severe airflow limitation [63]. For this reason, DPIs are not
recommended for children under the age of 5 years [60].
The newer active or power-assisted DPIs incorporate battery-
driven impellers and vibrating piezoelectric crystals that
reduce the need for the patient to generate a high inspiratory
flow rate, an advantage for many patients [59, 62]. Drug
delivery to the lung ranges between 10% and 40% of the
emitted dose for several marketed DPIs [60]. The physical
design of the DPI establishes its specific resistance to airflow
(measured as the square root of the pressure drop across
the device divided by the flow rate through the device),
with current designs having specific resistance values ranging
from about 0.02 to 0.2 cmH
2
O/L/min) [61]. To produce a
fine powder aerosol with increased delivery to the lung, a
DPI that is characterised as having a low resistance requires
an inspiratory flow of >90 L/min, a medium-resistance DPI
requires 50–60 L/min, and a high-resistance DPI requires
<50 L/min [61]. Of note, DPIs with high resistance tend to
produce greater lung deposition than those with a lower
resistance [61], but the clinical significance of this is not
known. Based on the previous considerations, it is recom-
mended to instruct patients to inhale forcefully from the
beginning of the inspiration deeply as much as possible
and to continue to inhale for as long as possible [12]. The
rationale for these recommendations is that when using
a DPI, inhalation should be forceful enough to disburse
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themicronised drug from the lactose-based carrier into a fine
particle dose. However, it is not the absolute inspiratory flow
that determines the fine particle dose from an inhaler but the
resulting energy, which also depends on inhaler resistance.
High air velocitieswithin the inhaler are required for effective
dispersion rather than high airflow through the inhaler. High
airflow through the inhaler will lead to increased impaction
in upper airways; thus, fast inhalation should be avoided
unless a larger fine particle fraction compensates for the
increased impaction. Furthermore, when using a singledose
DPI, it is also recommendable to instruct patients to perform
two separate inhalations for each dose [12].
Although DPIs offer advantages over pMDIs, they do
have some limitations (Table 1) of design, cost-effectiveness
and user-friendliness [60]. For instance, capsule-based DPIs,
such as the HandiHaler and the Aerolizer, require that
single doses are individually loaded into the inhaler imme-
diately before use. This is inconvenient for some patients
and does not allow direct dose counting. In addition, the
inhalation manoeuvre has to be repeated until the capsule
is empty, which may give rise to underdosing and to high
dose variability. Other DPIs are multiple unit dose devices,
such as the Diskhaler, or multidose devices, such as the
Diskus and the Turbuhaler. These devices do not have any
triggering mechanism which makes optimal drug delivery
entirely dependent on an individual patient’s uncontrolled
inspiratory manoeuvre. Because of variations in the design
and performance of DPIs, patients might not use all DPIs
equally well. Therefore, DPIs that dispense the same drug
might not be readily interchangeable [61]. Studies [59, 60]
have also been shown that dose emission is reduced when
a DPI is exposed to extremely low and high temperature
and humidity; therefore, DPIs should be stored in a cool dry
place.
A recent systematic literature review revealed that up
to 90% of patients did not use their DPI correctly [64].
Common errors made by patients were lack of exhalation
before inhalation, incorrect positioning and loading of the
inhaler, failure to inhale forcefully and deeply through the
device, and patients’ failure to breath-hold after inhalation
[64]. All these errors may lead to insufficient drug delivery,
which adversely influences drug efficacy and may contribute
to inadequate disease control [64]. It is unsurprising that
such a high proportion of patients were unable to use
DPIs correctly as the devices have many inherent design
limitations. The Diskhaler, for example, is a multiple unit
dose device as it contains a series of foil blisters on a disk.
It is complicated to use, requiring eight steps to effect one
correct inhalation; it has been shown that approximately
70% of patients are unable to use it correctly [64]. The
disks have to be changed frequently and the device cleaned
before refilling. In addition, it provides no feedback to the
patient of a successful inhalation, except a sweet taste in
the mouth which may simply be indicative of oral drug
deposition. The Turbuhaler, a multidose reservoir device,
is the most frequently prescribed DPI as it produces good
deposition of the drug in the lungs provided that a sufficient
(about 60 L/min) inspiratory flow has been achieved by the
patients. However, approximately 80% of patients are unable
to use it correctly [64]; common mistakes made by patients
using this inhaler are failure to turn the base fully in both
directions and failure to keep the device upright until loaded.
In addition, due to its high intrinsic resistance, patients who
have a reduced inspiratory flow may encounter problems
using this device.TheDiskus is another example ofmultidose
device that uses a strip foil drug containing blisters. As many
as 50% of patients use this DPI incorrectly, and common
errors include failure or difficulty in loading the device before
inhalation and exhaling into the device [64]. The Diskus
has a low intrinsic resistance but, like the Turbuhaler, does
not have any triggering mechanism which makes optimal
drug delivery entirely dependent on an individual patient’s
uncontrolled inspiratory manoeuvre [64]. Additionally, as
with other DPI devices employing drug blisters, incomplete
emptying of themetered dosemay occur, which could reduce
the amount of drug delivered to the lung and hence reduce
clinical efficacy [64].
2.5. Nebulisers. Various types of nebulisers are available on
the market, and several studies have indicated that per-
formance varies between manufacturers and also between
nebulisers from the same manufacturers [65–67]. There are
two basic types (Figure 4) of nebulisers: the pneumatic or
jet nebuliser and the ultrasonic nebulisers [65–67]. The jet
nebulisers generate aerosol particles as a result of the impact
between a liquid and a jet of high velocity gas (usually air
or oxygen) in the nebuliser chamber. In a jet nebulizer, the
driving gas passes through a very narrow hole from a high
pressure system. At the narrow hole, the pressure falls and the
gas velocity increases greatly producing a cone shaped front.
This passes at high velocity over the end of a narrow liquid
feed tube or concentric feeding system creating a negative
pressure at this point. As a result of this fall in pressure, liquid
is sucked up by the Bernoulli effect and is drawn out into fine
ligaments. The ligaments then collapse into droplets under
the influence of the surface tension.Themajority of the liquid
mass produced during this process is in the form of large (15–
500 micron) nonrespirable droplets. Coarse droplets impact
on baffles while smaller droplets may be inhaled or may land
on internal walls returning to the reservoir for renebulisation
[65–67].The resultant large particles then impact upon baffles
to generate small, respirable particles. Thus, baffle design
has a critical effect on droplet size. Concentric liquid feeds
minimise blockage by residual drug build-up with repeated
nebulisation. A flat pick up plate may allow some nebulisers
to be tilted during treatment whilst maintaining liquid flow
from the reservoir. A 6–8 L/min flow and a fill volume of 4-
5mL are generally recommended, unless some nebulisers are
specifically designed for different flow and a smaller or larger
fill volume [68]. The volume of some unit-dose medications
is suboptimal; ideally, saline should be added to bring the fill
volume to 4-5mL, but this might not be practical. The longer
nebulisation time with a greater fill volume can be reduced
by increasing the flow used to power the nebuliser; however,
increasing the flow decreases the droplet size produced by
the nebuliser. Dead volume is the volume that is trapped
inside the nebulizer, and typically it is 0.5–1mL. To reduce
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Figure 4: Components of a jet (a) and an ultrasonic (b) nebulisers. Modified from O’Callaghan and Barry [65].
dead volume, clinicians and patients commonly tap the
nebuliser periodically during therapy in an effort to increase
nebuliser output [69]. Therapy may also be continued past
the point of sputtering in an attempt to decrease the dead
volume, but this is unproductive and not recommended [70].
Because of the evaporative loss within the nebuliser, the
solution becomes increasingly concentrated and cools during
nebulisation.
There are four different designs of the jet nebulisers: jet
nebuliser with reservoir tube, jet nebuliser with collection
bag, and breath-enhanced and breath-actuated jet nebulizers
[65–67]. Both the breath-enhanced and breath-actuated jet
nebulisers are modifications of the “conventional” jet neb-
ulisers specifically designed to improve their efficiency by
increasing the amount of aerosol delivered to the patient
with less wastage of aerosol during exhalation. The different
types of jet nebulisers have different output characteristics
determined by the design of the air jet and capillary tube
orifices, their geometric relationship with each other and the
internal baffles; for a given design the major determinant
of output is the driving pressure [65–67]. The jet nebulizer
with reservoir tube provides continuous aerosol during the
entire breathing cycle, causing the release of aerosol to
ambient air during exhalation and anytime when the patient
is not breathing. Consequently, no more than 20% of the
emitted aerosol is inhaled [65–67]. The jet nebulizer with
collection bag generates aerosol by continuously filling a
collection bag that acts as a reservoir. The patient inhales
aerosol from the reservoir through a one-way inspiratory
valve and exhales to the environment through an exhala-
tion port between the one-way inspiratory valve and the
mouthpiece. The breath-enhanced jet nebulizer (e.g., the
PARI LC Plus, PARI gmbH) uses two one-way valves to
prevent the loss of aerosol to environment. When the patient
inhales, the inspiratory valve opens and aerosol vents through
the nebuliser; exhaled aerosol passes through an expiratory
valve in the mouthpiece. Breath-actuated jet nebulisers are
designed to increase aerosol delivery to patient by means of
a breath-actuated valve that triggers aerosol generation only
during inspiration. Both the breath-enhanced and breath-
actuated nebulisers increase the amount of inspired aerosol
with shorter nebulisation time than “conventional” jet nebu-
lisers [65]. Recently, adaptive aerosol delivery nebulisers (the
HaloLite and the Prodose) have been developed to reduce the
variability of the delivered dose and the waste of aerosol to
the environment and to facilitate monitoring of compliance
with patient therapy [71–73]. Bymonitoring pressure changes
relative to flow over the first three breaths, these delivery
systems establish the shape of the breathing pattern and then
use this to provide a timed pulse of aerosol during the first
50% of each tidal inspiration. Monitoring of the breathing
pattern continues throughout the delivery period, and any
changes in breathing pattern are taken into account during
the remainder of the delivery period. Furthermore, if no
inhalation is registered, the system will cease delivery until
the patient recommences breathing on the system [71–73].
Since the pulsed dose is only provided in the first 50% of
each breath and the software can calculate the amount of drug
given per pulse, the precise dose of drug can be delivered
before the system stops [71–73].
Ultrasonic nebulisers use a rapidly (>1MHz) vibrating
piezoelectric crystal to produce aerosol particles [65–67].
Ultrasonic vibrations from the crystal are transmitted to
the surface of the drug solution where standing waves are
formed. Droplets break free from the crest of these waves
and are released as aerosol. The size of droplets produced by
ultrasonic nebuliser is related to the frequency of oscillation
[65–67]. Although ultrasonic nebulisers can nebulise solu-
tions more quickly than jet nebulisers, they are not suitable
for suspensions and the piezoelectric crystal can heat the
drug to be aerosolised. A relatively new ultrasonic nebuliser
technology is represented by the vibrating mesh nebulisers
[12, 74, 75].These new-generation nebulisers are either active
or passive systems. In active devices (e.g., the eFlow, PARI
gmbH), the aperture plate vibrates at a high frequency and
draws the solution through the apertures in the plate. In
passively vibrating mesh devices (e.g., MicroAir, Omron
Healthcare), the mesh is attached to a transducer horn and
vibrations of the piezoelectric crystal that are transmitted
via the transducer horn force the solution through the mesh
to create an aerosol. The eFlow is designed to be used with
either a very low residual volume to reduce drug waste or
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Figure 5: The Respimat soft mist inhaler. From [81].
with a relatively large residual volume, so that it can be
used instead of conventional jet nebulisers with the same
fill volume [76]. Vibrating mesh devices have a number of
advantages over other nebuliser systems: they have greater
efficiency, precision and consistency of drug delivery, and are
quiet and generally portable [74, 75]. However, they are also
significantly more expensive than other types of nebulisers,
and require a significant amount ofmaintenance and cleaning
after each use to prevent build-up of deposit and blockage of
the apertures especiallywhen suspensions are aerosolised and
to prevent colonisation by pathogens [75]. They are currently
most widely used for the treatment of patients with cystic
fibrosis [77].
Generally, mouthpieces are employed during nebuliser
delivery. However, facemasks may be necessary for treatment
of acutely dyspnoeic patients or uncooperative patients, such
as infants and toddlers [78]. The facemask is not just a
connector between the device and the patient. Principles
of mask design are different depending on the device [78].
For example, a valved holding chamber with facemask must
have a tight seal to achieve optimal lung deposition [78]. In
contrast, the facemask for a nebuliser should not incorporate
a tight seal but should have vent holes to reduce deposition on
the face and in the eyes [79, 80]. Improvements in facemask
design provide greater inhaled mass while reducing facial
and ocular deposition [78]. Often, when a patient does not
tolerate the facemask, practitioners employ the “blow-by”
technique, which simply directs the aerosol towards the nose
andmouth with the mouthpiece. However, there is no data to
indicate that this is an effective method for delivering aerosol
to the lungs, and therefore the use of this technique is not
recommended [12].
Unlike pMDIs andDPIs, no special inhalation techniques
are needed for optimum delivery with conventional neb-
ulisers; tidal breathing with only occasional deep breaths
is sufficient (Table 1). Thus, for patients who are unable
to master the proper pMDI technique despite repeated
instruction, the proper use of a nebuliser probably improves
drug delivery. However, nebulisers have some distinct dis-
advantages. Patients must load the device with medication
solution for each treatment, and bacterial contamination of
the reservoir can cause respiratory infection [65–67], making
regular cleaning important. Also, nebuliser treatments take
longer time than pMDIs and DPIs for drug administration
(10–15min for a jet nebuliser, 5min for an ultrasonic or mesh
nebuliser). Although they are relatively portable, typical jet
nebuliser must be plugged into a wall outlet or power adaptor
and thus cannot be used easily in transit.
2.6. Soft Mist Inhalers. The development of soft mist inhalers
(SMIs) has opened up new opportunities for inhaled drug
delivery. Technically, these inhalation devices do fall within
the definition of a nebuliser, as they transform aqueous liquid
solution to liquid aerosol droplets suitable for inhalation.
However, at variance with the traditional nebuliser designs,
SMIs are hand-held multidose devices that have the potential
to compete with both pMDIs and DPIs in the portable
inhaler market. At the present, the only SMI currently
marketed in some European countries is the Respimat
inhaler (Boehringer Ingelheim, Figure 5). This device does
not require propellants since it is powered by the energy
of a compressed spring inside the inhaler. Individual doses
are delivered via a precisely engineered nozzle system as a
slow-moving aerosol cloud (hence the term “soft mist”) [81].
Scintigraphic studies have shown that, compared to a CFC-
based pMDI, lung deposition is higher (up to 50%) and
oropharyngeal deposition is lower [81]. Respimat is a “press
and breathe” device, and the correct inhalation technique
closely resembles that used with a pMDI. However, although
coordination between firing and inhaling is required, the
aerosol emitted from Respimat is released very slowly, with
a velocity of approximately four times less than that observed
with a CFC-driven pMDI [81]. This greatly reduces the
potential for drug impaction in the oropharynx. In addition,
the relatively long duration over which the dose is expelled
from Respimat (about 1.2 s compared with 0.1 s from pMDIs)
would be expected to greatly reduce the need to coordinate
actuation and inspiration, thus improving the potential for
greater lung deposition. Although Respimat has been used
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relatively little in clinical practice to date, clinical trials seem
to confirm that drugs delivered by the Respimat are effective
in correspondingly smaller doses in patients with obstructive
airway disease [82].
3. Choice of an Inhaler Device for
Asthma Therapy
Drug choice is usually the first step in prescribing inhaled
therapy for asthma and, together with availability and reim-
bursement criteria, dictates the inhaler deliver options. The
next two steps, choice of inhaler device type and patient
training in the use of the inhaler, are hampered by the
lack of robust evidence or effective tools to aid healthcare
professionals [9, 10, 83].Meta-analysis regarding the selection
of aerosol delivery systems for acute asthma concluded that
short-acting beta agonists delivered via either nebuliser or
pMDI with handling chamber are essentially equivalent [84–
88]. More than 100 inhaled device-drug combinations are
currently available for treatment of asthmatic patients [57].
The number is likely to increase with the development of ana-
logue inhaled drugs delivered by relatively low-cost pMDIs
and DPIs. Consequently, the level of confusion experienced
by clinicians, nurses, and pharmacists when trying to choose
the most appropriate device for each patient is increased.
Thus, physicians’ experience is amongst the most important
factors which influence decisionmaking for inhaler choice in
asthma therapy. In fact, inhalers are often prescribed on an
empirical basis rather than on an evidence-based approach.
Following their own experience, doctors aremuchmore likely
to prescribe the same old inhaler which they have always
prescribed rather than new, improved inhalers entering the
market.
Current asthma management guidelines give some guid-
ance on the class of inhaler to prescribe to children, but
they offer nonspecific advice regarding inhaler choice for
adult patients. The GINA guidelines [1] recommend pMDIs
with spacer and facemask for children younger than 4 years
(or pMDIs with spacer and mouthpiece for those aged 4–6
years) and, in addition to pMDIs alone, DPIs or BAMDIs,
for children older than 6 years. However, for adults, the same
guidelines state that inhalers should be portable and simple
to use, should not require an external power source, require
minimal cooperation and coordination, and have minimal
maintenance requirements [1]. The British Thoracic Society
guidelines [2] also include patient’s preference and abilities
to use the device correctly. However, this advice relating
to patient preference is not supported by any evidence that
patients will correctly use an inhaler that they like.
Criteria to be considered when choosing an inhaler
device differ depending on the audience addressed [89].
From the viewpoint of the inhalation technologist, consistent
and safe dosing, sufficient drug deposition, and clinical
effect guide the inhaler choice. The patient’s ability to inhale
through the device, the intrinsic airflow resistance of the
device, and the degree of dependence of drug release on
inspiratory airflow variability are all important determinants
when considering constancy of dosing [89]. From the point
of view of the clinician, clinical efficacy and safety should be
the most important determinants to consider when choosing
an inhaler [89]. However, in the real word clinical efficacy
must be balanced against cost-effectiveness, and inhalers
with insufficient performance may be prescribed simply
because they are cheap. Patients’ preferences and acceptance
of the inhaler should also be considered when deciding on a
specific inhaler since these will have major implications for
compliance.
Several general principles of inhaler selection and use
have recently been addressed in an evidence-based systematic
review by a joint committee of the American College of Chest
Physicians and the American College of Asthma, Allergy
and Immunology [13]. The bottom line of this document
was that each of the aerosol devices can work equally well
in various clinical settings with patients who can use these
devices properly [13]. In addition, pMDIs are convenient
for delivering a wide variety of drugs to a broad spectrum
of patients. For patients who have trouble coordinating
inhalation with inhaler actuation, the use of spacer may
obviate this difficulty, though most of these devices are
cumbersome to store and transport [13]. The use of spacer,
however, is mandatory for infants and young children. Dry
powder inhalers are usually easier for patients to handle than
pMDIs, and a growing number of drug types are available
in several DPI formats [13]. The key issue for dry powder
inhalation is the minimum inspiratory flow rate below which
deagglomeration is inefficient, resulting in a reduced drug
delivered dose. The most ill patients and the very young may
not be candidates for a DPI. A nebuliser could be used as
an adequate alternative to pMDI with a spacer by almost
any patient in a variety of clinical settings from the home
to the intensive care unit [13]. However, nebulisers are more
expensive, cumbersome, and relatively time-consuming to
use compared to hand-held inhalers. These attributes should
limit the use of nebulisers whose effect can be matched
by hand-held devices in almost all clinical settings. The
findings of this document should not be interpreted to
mean that the device choice for a specific patient does not
matter. Rather, the study simply says that each of the devices
studied can work equally well in patients who can use them
correctly. However, this evidence-based systematic review
does not provide much information about who is likely
to use one device or another properly nor does it address
many other considerations that are important for choosing
a delivery device for a specific patient in a specific clinical
situation. These include the patient’s ability to use the device,
patient preference, and the availability of equipment and
cost.
More recently, Chapman and coworkers [90] proposed
an algorithm approach to inhaler selection that considers
patient’s ability to generate an inspiratory flow rate>30 L/min
to coordinate inhaler actuation and inspiration and to prepare
and actuate the device (Table 2).
When choosing an inhaler for children, it is essential
that the individual child receives appropriate instructions
and training necessary for the management of the disease
[91]. Furthermore, the child should be prescribed the correct
medication tailored to the severity of the disease, and, most
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Table 2: Choice of inhaler devices according to the patient’s
inspiratory flow and ability to coordinate inhaler actuation and
inhalation. Modified from Chapman et al. [90].
Good hand-lung coordination Poor hand-lung coordination
Inspiratory
flow >
30 L/min
Inspiratory
flow <
30 L/min
Inspiratory
flow >
30 L/min
Inspiratory
flow <
30 L/min
pMDI pMDI pMDI + spacer pMDI + spacer
BAMDI Nebuliser BAMDI Nebuliser
DPI SMI DPI SMI
Nebuliser Nebuliser
SMI SMI
pMDI: pressurised metered-dose inhalers; BAMDI: breath-actuated
metered-dose inhaler; DPI: dry powder inhaler; SMI: soft mist inhaler.
importantly, the prescribed inhaler should suit the individual
needs and preference of the child [91]. Contrary to general
opinion, using an inhaler may be difficult for children [91];
many children with asthma use their inhaler incorrectly
which may result in unreliable drug delivery, even after
instruction and training for correct inhalation. In addition,
previous inhalation instruction may be forgotten and, there-
fore, training should be repeated regularly tomaintain correct
inhalation technique in children with asthma [91].
4. Education and Instruction
Successful asthma management is 10% medication and 90%
education [92]. Asthma education empowers patients to
manage their disease and increases their awareness of danger
signs [93]. Patients with a positive attitude towards con-
trolling their asthma are more likely to adhere to therapy
[94]. Regular medical review provides an opportunity to
raise patients’ expectations, helps them understand how to
monitor their asthma, and increases awareness of possible
factors, such as poor inhaler technique, that may prevent
them from attaining control [93]. A key challenge in many
practice situations is the allocation of personnel and time
for patient training in inhaler technique, although the
upfront investment in time to properly train could later save
time, resources, and adverse patient impact by preventing
uncontrolled asthma because of poor inhaler technique. The
conventional wisdom is that training patients to use inhalers
is time-consuming. However, in one study, training sessions
provided by pharmacists took an average of only 2.5min and
were shown to improve asthma outcomes [95]. The “trainer”
must know the proper technique, including refinements to
optimise inhaler therapy for each device type prescribed.
However, the healthcare professionals involved often have not
mastered inhalation technique themselves [96, 97] and are
not sufficiently aware of handling difficulties with devices
other than pMDIs [98]. Furthermore, only 2 of the 40
medical textbooks include a simple list of steps to properly
use a pMDI [11]. For this reason, studies have examined
educational interventions designed to “train the trainer”
and improve healthcare professional inhaler competence.
It has been demonstrated that a single education session
improves medical residents’ inhaler knowledge and skills
[99]. Another study demonstrated that pharmacists who
participate in a single-session education workshop showed
significantly better knowledge and skills than a control
group and that this knowledge was retained at a high level
[100]. The best person to provide inhaler training (physi-
cian, nurse, or pharmacist) will vary by practice situation.
Another option is to enlist the aid of lay educators (e.g.,
other patients) to provide support and training. In all cases,
adequate time and resources must be allotted for the training
sessions. Successful training in inhaler technique depends
upon effective communication of proper technique and its
purpose and monitoring to ensure that the skills have been
learned and retained [101]. Of all the training approaches
possible, personal or small group demonstration has so far
proven most effective [102, 103]. Other training methods
for inhaler use include written indications, illustrations,
audio-visual demonstrations, and internet-based, interactive,
multimedia tutorials, the latter representing a promising,
new low-cost and time-savingmechanism for educating both
patients and healthcare professionals [104]. However, their
value must not be overestimated, as a substantial proportion
of patients still have incorrect inhalation technique despite
several training sessions [105] Periodic retraining is needed
as inhaler technique deteriorates with time [104, 106]. Special
provision should be made for the elderly, who may have
more trouble learning good inhaler technique and a greater
tendency to forget it, while small children may require a
particular teaching environment to hold their attention [107,
108]. Intuitively, therapeutic success will be more likely if
patients are prescribed a device that they have chosen, are
happy with, and can use well. Although use of a single type
of device to deliver all medications is not always practicable
it is preferable since coping with a variety of devices increases
the likelihood of error [109].
A visual evaluation by the healthcare professionals is
subjective but important in assessing inhaler preparation and
the mechanics of inhaler handling by the patient. Indeed,
in real life, patients make many errors with their usual
inhalation device that may negate the benefits observed in
clinical trials. A checklist to identify critical errors, which
are those comprising treatment efficacy, could be applied
here, as outlined by Molimard and Le Gros [110]. Exam-
ples of currently available tools to objectively check and
maintain the correct inhalation pattern include the Aerosol
InhalationMonitor (Vitalograph Ltd., Buckingham, UK) and
2Tone Trainer (Canday Medical Ltd., Newmarket, UK) for
MDIs and the In-Check Dial (Clement Clarke International,
Harlow, UK) for DPIs [111, 112]. These tools can provide an
objective evaluation of the inhalation profile but cannot assess
the patient’s preparation and handling of their device.
5. ADMIT Recommendations
Many physicians in Europe are fully aware of the difficulties
that patients have using prescribed inhaler devices correctly
and the negative impact that thismay have on asthma control.
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TheAerosol DrugManagement Improvement Team (ADMIT),
a consortium of European respiratory physicians (respiratory
specialists, general practitioners, and paediatricians) with
a common interest in promoting excellent delivery of inhaled
drugs, was formed with the remit of examining ways to
improve treatment of obstructive airway disease in Europe
[57]. ADMIT recommends that instructions for correct
inhalation technique for each inhaler device currently on
the market should be compiled by an Official Board with
instructionsmade readily accessible on theweb. Local asthma
associations and patient groups could also be involved in
promoting the importance and teaching and reinforcing of
correct inhalation technique. Information could be dissem-
inated by the use of dedicated literature, school visits by
healthcare professionals, pharmacists, and through patient
advocacy groups. Other ADMIT recommendations are sum-
marised as follows.
Recommendations from the Aerosol Drug Management
Improvement Team (ADMIT) for the choice and correct
usage of inhalers. (DPI, dry powder inhaler; PIF, peak
inspiratory flow; pMDI, pressurised metered-dose inhaler.
Modified from Crompton et al. [8].)
(i) Inhalers should be matched to the patient as much as
possible.
(ii) In young children, pMDIs should be always used with
a spacer device.
(iii) An alternative to a pMDI should be considered in
elderly patients with a minimental test score <23/30
or an ideomotor dyspraxia score <14/20 as they are
unlikely to have correct inhalation technique through
a pMDI.
(iv) The patient’s PIF values should be considered before
DPI prescription. Those patients with severe air-
flow obstruction, children, and the elderly would
benefit from an inhaler device with a low airflow
resistance.
(v) Before prescribing a DPI, check that the patient can
inhale deeply and forcibly at the start of the inspira-
tion as airflow profile affects particle size produced
and hence drug deposition and efficacy.
(vi) Where possible, one patient should have one type of
inhaler.
(vii) Establish anOfficial Board to compile instructions for
correct inhalation technique for each inhaler device
currently on the market.
(viii) Instructions for correct inhaler use should be made
readily accessible on a dedicated web site.
(x) Training in correct inhalation technique is essential
for patients and healthcare professionals.
(xi) Inhalation technique should be checked and rein-
forced at regular intervals.
(xii) Teaching correct inhalation techniques should be
tailored to the patient’s needs and preferences: group
instruction in correct inhalation technique appears to
be more effective than personal one-to-one instruc-
tion and equally effective like video instruction;
younger patients may benefit more from multimedia
teaching methods; elderly patients respond well to
one-to-one tuition.
The ADMIT has also proposed a practical algorithm
(Figure 6) in order to improve the instruction given to the
patient regarding optimal use of their inhalers. At each
consultation of the patient, the physician should establish
the patient’s level of symptoms and control, ideally using a
composite measure such as the GINA control assessment
[1], and if well controlled for at least 3 months, therapy
should be stepped down gradually according to treatment
guidelines. Conversely, if the patient answers “no” to any
of these checklist questions then compliance and aggravat-
ing (trigger) factors should be assessed. Most importantly,
inhalation technique should be assessed. If the patient is
unable to use a particular inhaler correctly despite repeated
attempts, a change in inhaler device should be considered.
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In the cases where ongoing uncontrolled asthma persists in
the face of correct inhaler technique, then asthma therapy
should be stepped up according to the treatment guide-
lines and another appointment scheduled in order to check
symptoms.
6. Conclusions
The prevalence of asthma is continuing to rise through-
out the world, particularly amongst children. Despite the
implementation of both national and international guidelines
and the widespread availability of effective pharmacological
therapy, asthma is frequently uncontrolled and still may cause
death. The reasons for this anomaly are numerous. First, the
guidelines themselves are complex and too long for most
physicians to absorb and utilise excessive length. Secondly,
patients frequently do not adhere to their treatment regimen
for a variety of reasons including incorrect use of inhaler and
underestimation of disease severity. Indeed, asthma severity
is oftenmisclassified in the first instance and inappropriate or
insufficient therapy prescribed. Finally, although guidelines
agree on the most appropriate therapy to control asthma, the
method bywhich this therapy is delivered to the lungs is often
lacking in detail.
To date, advancement in asthma management has been
pharmacologically driven rather than device driven. Since it
is likely that in the future inhaled bronchodilators and cor-
ticosteroids will remain the cornerstone of asthma therapy,
development of inhaler devices may becomemore important
than development of new drugs. In the past 10–15 years,
several innovative developments have advanced the field of
inhaler design. Although many inhalers incorporate features
providing efficient aerosol delivery for asthma treatment,
there is no perfect inhaler and each has advantages and
disadvantages, but there is increasing recognition that a
successful clinical outcome is determined as much by choice
of an appropriate inhaler device as by the drugs that go in
them. Drug delivery from all inhaler devices depends on
how the patient prepares the device and then inhales from
it. Problems with drug delivery have been identified due
to inappropriate use of inhaler devices, particularly pMDIs
where patients need to coordinate inhaler activation with
inspiration. However, as inhalation is likely to remain the
delivery route of choice for the foreseeable future, there is
a need to develop inhaler devices which are easy to use
and deliver a consistent dose of drug to the lungs which
may improve patient compliance with treatment leading to
better control of asthma. There is evidence that a patient
is most likely to use correctly an inhaler that he or she
prefers, and each patient’s choice of device will be deter-
mined by individual perceptions of how its advantages and
disadvantages balance out. This decision could be quite
different to the judgment of a prescriber or a formulator,
who may give more weight to technical points. Choice of
an inhaler device should therefore take into account the
likelihood that patients will be able to use a particular
device correctly, cost-effectiveness, preference, and likely
compliance.
Continued and repeated education of both healthcare
professionals and patients in correct inhalation technique is
essential, and the results are checked at regular intervals by
a member of medical staff. Substantial changes in educa-
tional efforts are clearly required and should be particularly
addressed towards the general practitioner and asthma nurse
who in turn teach patients how to use their inhaler correctly.
Finally, it is important to remember that continually changing
inhaler devices which deliver the same drug is not the
answer, as patients lose confidence in both the device and
the drug and compliance with therapy drops. An inhaler
should only be prescribed with the absolute certainly that
the patient can use it correctly. It should be stressed that
once a patient is familiar and stabilised on one type of
inhaler, they should not be switched to new devices without
their involvement and without follow-up education on how
to use the device properly. A recent study has shown that
asthma control deteriorates if an inhaler is substituted for
a different device at the prescribing or dispensing stage
without involving the patient [113]. Prescribers should be
especially vigilant on this point in order to avoid changes
to the type of device their patients receive through the
pharmacy.
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